Long-term Use of Omedar
The long-term use of this medicine may lead to a decrease in the absorption of vitamin
Use of Methotrexate
These patients are at increased risk when using this medicine. The use of proton pump inhibitors with methotrexate may increase the level of methotrexate in the blood. Patients should temporarily stop the use of proton pump inhibitors during intake of the high dose of methotrexate.
False Positive Results for Neuroendocrine Tumors
Such patients are at increased risk when using this medicine. Omedar causes an increase in chromogranin A (CGA) protein levels in the blood that lead to false positive results for abnormal growth of the cells of the endocrine and nervous system (neuroendocrine tumors
). It is advised to stop Omedar treatment temporarily before examining CGA levels and in case if initial levels of CGA are high, then the test should be repeated.
Use of Antidepressants and Antibacterial Drugs
Patients using antidepressants
and antibacterial (rifampin) drugs are at an increased risk when using this medicine. In such patients, the levels of Omedar is decreased. The patients should avoid using Omedar with these medicines.
Low Magnesium Levels in the Blood
These patients are at increased risk when using this medicine. Such patients may suffer from severe side effects like heart palpitation
and uncontrolled contractions of the muscles. Careful monitoring of magnesium levels is required before initiating the treatment.
Use of Clopidogrel (Antiplatelet Medicine)
These patients are at increased risk when using this medicine. Omedar prevents the antiplatelet effect of clopidogrel. These patients should not take Omedar and clopidogrel together.
Patients using this medicine are at increased risk for developing weak bone-related fractures
of the hip, wrist, or spine. Low dose should be given to these patients for a shorter duration.
Bacterium Associated Diarrhea
Patients using this medicine are at increased risk of developing Clostridium difficile associated diarrhea
. Low dose should be given to these patients for a shorter duration.
Severe Inflammation of the Stomach (Atrophic Gastritis)
Such patients are at increased risk of developing stomach cancer
when using this medicine.
Stomach Cancer (Gastric Malignancy)
Treatment with Omedar does not prevent the presence of stomach ulcers
in these patients.
Use of Other Proton Pump Inhibitors
Such patients are at an increased risk when using this medicine. These patients may suffer from subacute cutaneous lupus
erythematosus, the disease in which the body's immune system attacks the healthy skin cells. Avoid use of this medicine after consultation with the doctor.